By Delilah Alvarado | Published November 9, 2026
In a significant validation of its long-term research strategy, Vir Biotechnology announced on Sunday that its experimental two-drug combination for the treatment of chronic hepatitis D virus (HDV) has successfully met all primary and secondary endpoints in the pivotal Phase 3 ECLIPSE-1 trial. The results, which highlight the efficacy of the investigative regimen elebsiran and tobevibart, arrive at a transformative moment for the company, which has spent the last several years aggressively shifting its focus from infectious disease to oncology.
The clinical data, which demonstrated a robust viral response, has sparked optimism among investors and industry analysts. Shares of Vir Biotechnology climbed approximately 12% in early Monday trading, reflecting market confidence in the drug’s potential to become a dominant, front-line therapy in a space that has historically been defined by a significant lack of effective treatment options.
Main Facts: The ECLIPSE-1 Success
The ECLIPSE-1 trial was designed to evaluate the safety and efficacy of the combination of elebsiran, an RNA interference (RNAi) therapeutic, and tobevibart, a monoclonal antibody. The primary endpoint of the study focused on the combination’s ability to achieve a "virologic and biochemical response"—defined as the elimination of detectable signs of the virus combined with the normalization of alanine aminotransferase (ALT), a critical liver enzyme.
According to the data released by Vir, 44% of patients receiving the active treatment achieved this primary endpoint after 48 weeks. In stark contrast, zero patients in the "delayed treatment" control group achieved these results, underscoring the clinical potency of the regimen. Furthermore, the combination met a key secondary endpoint, with 79% of treated patients showing a significant reduction in viral load.
This success is particularly notable given the complexities of treating HDV, a satellite virus that relies on the hepatitis B virus (HBV) to replicate. Because HDV exacerbates the progression of liver disease, leading to faster rates of cirrhosis, liver failure, and hepatocellular carcinoma, the ability to achieve a sustained virologic response is considered a "holy grail" for hepatologists.
Chronology: From COVID-19 to Chronic Viral Persistence
Vir Biotechnology’s trajectory over the past five years has been anything but conventional. Founded on the promise of innovative immunology, the company achieved global recognition in 2021 with the successful market launch of Xevudy, an antibody treatment for COVID-19. However, as the pandemic-era demand for COVID therapeutics waned, the company’s leadership team opted for a significant strategic pivot.
The Shift to Oncology
Following the decline of its COVID-19 franchise, Vir underwent a major restructuring. The company redirected its core R&D resources toward the development of T-cell engagers—a specialized class of cancer immunotherapies—and moved away from its broad infectious disease portfolio.
The "Holdout" Programs
Despite this pivot, Vir made the deliberate decision to retain two specific areas of its legacy research: preclinical HIV work and the late-stage development of its HDV portfolio. This decision, which some industry skeptics initially questioned, now appears to be the company’s most valuable hedge.
The ECLIPSE-1 results confirm that while Vir is now primarily an oncology-focused entity, its institutional expertise in viral immunology remains a core competency. The company currently has two additional Phase 3 trials ongoing for the same HDV regimen; data from these studies is expected in early 2027. If those results corroborate the findings from ECLIPSE-1, Vir intends to initiate a regulatory filing with the U.S. Food and Drug Administration (FDA) later that year.
The Landscape of Hepatitis D Treatment
Chronic hepatitis D is a rare but severe condition. While global prevalence estimates suggest that roughly 5% of the 250 million people living with chronic hepatitis B worldwide are co-infected with HDV, the disease remains underdiagnosed and historically underserved.
A Rapidly Evolving Competitive Field
Until recently, the treatment landscape for HDV was virtually non-existent. That changed earlier this year when the FDA granted approval to Gilead Sciences’ Hepcludex, a once-daily injection. Hepcludex was the first drug to receive regulatory backing specifically for HDV, marking a paradigm shift for patients.
However, the field is becoming increasingly crowded. In September 2026, Mirum Pharmaceuticals announced that its own candidate, acquired through a strategic buyout, met its primary endpoint in a Phase 3 trial. These developments indicate that the "orphan" status of HDV is ending, and the market is transitioning into a competitive environment where head-to-head clinical efficacy will determine long-term commercial success.
Analyst Implications: The Potential for Market Dominance
The reaction from the investment community has been overwhelmingly positive. Evercore ISI analyst Cory Kasimov, in a note to clients on Monday, characterized the Vir data as a "best-in-class" result.
"Cross-trial caveats always apply when comparing data across different studies, but the gap in efficacy is wide," Kasimov noted. He emphasized that the combination of elebsiran and tobevibart is well-positioned to become the "preferred" medicine for the condition. Should the drug receive approval, Kasimov believes it has the "potential to become a dominant front-line product," largely due to the strength of the 48-week response data.
The implication for Vir is clear: the company is successfully executing a "barbell" strategy. By maintaining a high-risk, high-reward oncology pipeline alongside a high-conviction, late-stage infectious disease asset, Vir is effectively diversifying its risk.
Clinical and Public Health Implications
The importance of the ECLIPSE-1 results extends beyond financial metrics. For patients, the prospect of a treatment that can normalize liver enzymes and suppress the virus is life-altering.
Understanding the Mechanism
The combination approach is unique. Elebsiran targets the replication cycle of the virus by interfering with the RNA, while tobevibart acts as an antibody to prevent viral entry into liver cells. By attacking the virus from two different angles, Vir is attempting to prevent the "escape" mutations that often render single-drug therapies ineffective over time.
Addressing the "Superinfection"
As noted by the Centers for Disease Control and Prevention (CDC), HDV infections often occur as a "superinfection" in patients already living with hepatitis B. These patients are at an accelerated risk of liver fibrosis and organ failure. The current standard of care has been limited by either poor tolerability or moderate efficacy. Vir’s regimen, if proven safe across a broader population in the remaining Phase 3 trials, could offer a more tolerable and effective alternative, potentially reducing the burden of liver transplants associated with chronic HDV.
Looking Ahead: The Path to 2027
The next twelve months will be critical for Vir Biotechnology. With two additional pivotal trials underway, the company is under pressure to maintain the high standard set by ECLIPSE-1. Regulatory bodies, including the FDA and the European Medicines Agency (EMA), will be scrutinizing the safety profile of the combined regimen, particularly the long-term impacts of the RNAi component.
For Vir, the transition from a COVID-centric company to a multi-faceted biopharmaceutical player is nearing a significant milestone. If the company can successfully bring its HDV therapy to market, it will have demonstrated that a "pivot" does not have to mean a total abandonment of past expertise—rather, it can be a strategic evolution that preserves value while pursuing new horizons in cancer therapy.
As the scientific community awaits the full dataset from the upcoming trials, the message from the market is clear: Vir has successfully navigated a difficult transition, and in doing so, may have unlocked the most effective treatment yet for one of the most challenging forms of viral hepatitis.
About the Author
